
    
      Subjects with chronic hepatitis C infections will be enrolled

      Inclusion Criteria

        1. Aged 18 y/o or older

        2. Positive for the HCV antibody and HCV RNA detected

        3. Patients with abnormal liver function OR a liver biopsy specimen taken in the 6 months
           prior to study entry showing chronic hepatitis, or liver fibrosis, or liver cihhrosis

        4. Have not been previously treated with pegylated-interferon and ribavirin for HCV

        5. Genotype 1 or Genotype 2

      Exclusion Criteria

        1. Subjects with decompensated liver disease

        2. With human immunodeficiency virus

        3. With hepatitis B infection

        4. With hemochromatosis defined by a pre-existing diagnosis of hemochromatosis or a
           positive HFE gene mutation or recipients of solid organ transplants

        5. With clinically significant cardiac or cardiovascular abnormalities, organ grafts,
           systemic infections, clinically significant bleeding disorders, evidence of malignant
           neoplastic diseases

        6. Subjects who are on lipid-lowering medications

        7. Poorly controlled Diabetes (A1C > 9%) The study will go through the CGMH IRB review and
           be posted into clinicaltrial.gov.

      This is a single centre, prospective, open-label, single arm, interventional study.
    
  